Announcement PDF ANNUAL 2026 REPORT ASX : RNV renerve.com.au Table of Contents About ReNerve 3 Chair’s Letter 5 Corporate Directory 9 Directors’ Report 10 Auditors’ Independent Declaration 26 Statement of Profit or Loss and Other Income 28 Statement of Financial Position 29 Statement of Changes in Equity 30 Statement of Cash flows 31 Directors’ Declaration 54 Independent Auditors’ Report 55 Shareholder Information 60 About ReNerve Limited ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide. Proven Clinical Success ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that’s changing lives. Comparison of Patient Pre & Post Surgery Pain Score Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs The comparison of pain scores between the two cohorts of patients 3.3 0.4 Comprehensive Product Portfolio ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs: On market • NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery. • Empliq™ Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases. • Empliq™ Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds. In development • NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends. • NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting. • NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve repairs. Market Leadership and Growth With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1 Vision and Values We’re not just developing medical devices – we’re engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body’s natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery. 1 Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) Chair's Letter Dear Shareholders, It is a privilege to write to you as Chair of ReNerve Limited following my appointment to the Board and subsequently as Non-Executive Chair. I would like to thank shareholders for their continued support as the Company advances its mission of transforming peripheral nerve repair through innovative medical technologies. My appointment forms part of the Board's renewal process and reflects our commitment to strong governance, strategic discipline and sustainable value creation. Over the past year, ReNerve has continued to successfully complete major company milestones over the past 12 months, continuing its strategy of expanding the commercial footprint of its FDA-cleared NervAlign® Nerve Cuff while progressing the broader product portfolio and strengthening the foundations required for long-term growth. The Board believes the Company is increasingly well positioned to participate in the significant global opportunity within peripheral nerve repair and regeneration. A major achievement during the period was the continued expansion of ReNerve's international market access. The Company secured marketing approvals for NervAlign® Nerve Cuff in Hong Kong, Malaysia, Indonesia, the Philippines and India, significantly broadening the potential patient population and creating multiple new commercial pathways across the Asia-Pacific region. These approvals represent important validation of our technology and provide a platform for future revenue growth through local distribution partnerships and surgeon adoption. ReNerve also continued to strengthen its commercial infrastructure. The establishment of additional distribution arrangements across strategic markets, together with the appointment of J4 as a second manufacturing partner for the Empliq product range, enhances the Company's ability to scale efficiently while maintaining supply chain resilience. These initiatives are important building blocks as we seek to increase market penetration and support future demand. From a financial and operational perspective, management delivered encouraging progress. For the June 2026 quarter, ReNerve reported record sales of approximately $211,000, and annual sales growth of 88% compared with the prior corresponding period. This outcome demonstrates growing market acceptance of the Company's products and provides further evidence that our commercialisation strategy is gaining momentum. The Company also took important steps to strengthen its balance sheet and funding flexibility through the execution of a funding facility of up to A$5 million with RiverFort. The facility provides access to growth capital that can support ongoing commercial expansion, product development initiatives and entry into new geographic markets. The Board remains focused on carefully managing capital while ensuring the Company has the resources required to pursue its strategic objectives. Alongside commercial progress, ReNerve continued to advance its innovation pipeline. During the year, the NervAlign® Nerve Guide Matrix program progressed into Stage 3 of commercial development, representing another important milestone in the Company's strategy to build a comprehensive portfolio addressing the spectrum of peripheral nerve injuries. The Board believes continued investment in differentiated products will be critical to creating long-term shareholder value and improving outcomes for patients globally. While we are pleased with the progress achieved, we remain focused on the work ahead. Our priorities include accelerating sales growth in existing markets, converting newly approved jurisdictions into meaningful revenue opportunities, further developing our product pipeline and maintaining disciplined capital management. We will also continue to strengthen governance and operational capabilities as ReNerve evolves from an emerging medical technology company into a broader commercial organisation. The need for innovative and effective nerve repair solutions remains substantial. With a growing international presence, a clinically validated flagship product, an expanding development pipeline and an experienced management team, ReNerve is well positioned to pursue this opportunity. Looking ahead, our focus is firmly on converting the foundations established to date into sustainable commercial growth and broader market adoption. Over the coming period, we will prioritise accelerating sales of NervAlign® Nerve Cuff in the United States, supporting our distribution partners and converting our expanding international regulatory approvals into new revenue opportunities. At the same time, we will continue to advance the NervAlign® Nerve Conduit and Nerve Guide Matrix through their respective development and clinical pathways, while building the evidence and market presence required to support future adoption. Importantly, we will remain disciplined in how we deploy capital and allocate resources, balancing investment in growth and innovation with the need to build a sustainable and increasingly valuable medical technology company. Our goal is clear: to expand ReNerve’s commercial footprint, broaden our product offering and strengthen our position as a leader in peripheral nerve repair. On behalf of the Board, I would like to thank our shareholders, clinicians, distribution partners, employees and management team for their dedication and support. Their commitment continues to drive ReNerve's progress and brings us closer to our vision of improving the lives of patients suffering from peripheral nerve injuries around the world. I look forward to updating shareholders on our continued progress in the year ahead. Yours sincerely, Maja McGuire Non-Executive Chair ReNerve Limited ReNerve Limited ABN 23 614 848 216 Annual Report - 30 June 2026 ReNerve Limited Corporate directory 30 June 2026 1 Directors Maja McGuire – Independent Chair & Director Dr Paul Savage – Independent Non-Executive Director Dr Julian Chick – Director & Chief Executive Officer Company secretary Mr David Lilja Notice of annual general meeting The details of the annual general meeting of ReNerve Limited are: Date: Monday 6th October 2026 Time: 2:00PM (AEDT) Location: To be confirmed Registered office DLK Advisory Pty Ltd, Level 10, 99 Queen Street Melbourne, 3000, Australia Principal place of business 157 Heidelberg Road Northcote VIC 3070, Australia Auditor William Buck Level 20, 181 William Street Melbourne VIC 3000, Australia Solicitors Cornwalls Level 4, 380 Collins Street Melbourne VIC 3000, Australia Bankers ANZ Ground Floor, 55 Collins Street Melbourne VIC 3000, Australia Bendigo Bank The Bendigo Centre Bendigo VIC 3550, Australia Stock exchange listing ReNerve Limited shares are listed on the Australian Securities Exchange (ASX code: RNV) Website https://renerve.com.au Corporate Governance Statement The directors and management are committed to conducting the business of ReNerve Limited in an ethical manner and in accordance with the highest standards of corporate governance. ReNerve Limited has adopted and has substantially complied with the ASX Corporate Governance Principles and Recommendations (Fourth Edition) (‘Recommendations’) to the extent appropriate to the size and nature of its operations. The company’s 2025 Corporate Governance Statement that sets out the corporate governance practices that were in operation during the financial year and identifies and explains any Recommendations that have not been followed, which is approved at the same time as the Annual Report, can be found at: https://renerve.com.au/company-policies/ ReNerve Limited Directors' report 30 June 2026 2 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'company') consisting of ReNerve Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026. Directors The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated: Ms Maja McGuire - Independent Chair & Non-Executive Director (Appointed 4 December 2025) Dr Paul Savage – Independent Non-Executive Director (Appointed 4 December 2025) Mr Reginald Stephen Cooper – Independent Chair & Non-Executive Director (Ceased 4 December 2025) Dr Michael Panaccio – Independent Non-Executive Director (Ceased 4 December 2025) Dr Julian Chick – Director & Chief Executive Officer Dr David Rhodes – Executive Director & Chief Scientific Officer (Ceased as Director 30 April 2026) Principal activities ReNerve has FDA market clearance and is selling its NervAlign® Nerve Cuff product in the US market. During FY2026, the company continued to broaden its commercial activities, with three product lines now being sold in the US and approvals obtained across several Asian markets. ReNerve remains focused on building a portfolio of regenerative biological based tissue products for the repair and replacement of injured peripheral nerves and related surgical procedures. ReNerve continues to develop its portfolio of medical devices used in the repair and/or replacement of damaged peripheral nerves, with three further product ranges at various stages of development: a) The NervAlign® Nerve Conduit range b) The NervAlign® Nerve Guide Matrix c) The NervAlign® Bionic Replacement Nerve In addition, ReNerve has expanded its commercial product range through the launch of the Empliq™ human tissue product range, comprising deep dermal and amniotic tissue products. These products are complementary to ReNerve’s existing nerve repair products, are sold through the company’s existing distribution channels, and are used in the same or related surgical procedures. Dividends There were no dividends paid, recommended or declared during the current or previous financial year. Review of operations The loss for the company after providing for income tax amounted to $5,572,439 (30 June 2025: $3,733,918). ReNerve Limited Directors' report 30 June 2026 3 During FY26, ReNerve progressed from a single-product commercial organisation to a multi-product regenerative medicine company, supported by expanding distribution networks, increasing hospital adoption, new international regulatory approvals and ongoing advancement of its development pipeline. The company believes these achievements position it favourably for continued commercial growth and product portfolio expansion. The 2026 financial year was a period of significant commercial and operational progress for ReNerve. The company delivered strong sales growth, expanded its portfolio of on-market products, established new commercial channels across the Asia- Pacific region and advanced the development of its next-generation peripheral nerve repair technologies. Full-year sales increased by 88% to approximately $510k, compared with $271k in FY25. Growth accelerated during the second half, culminating in record quarterly sales of $211,000 in the June quarter, an increase of more than 50% from the previous quarter and the company’s largest sales quarter to date. The growth reflected increasing adoption of the NervAlign® Nerve Cuff, the launch and commercial rollout of the Empliq™ human tissue product range and continued progress in securing new hospital approvals and purchasing approvals. ReNerve also expanded its geographic footprint beyond the United States through regulatory approvals and distribution partnerships in key Asia-Pacific markets. Alongside its commercial activities, the company continued to invest in the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix development programs. The Nerve Guide Matrix entered Stage 3 of ReNerve’s four-stage scaled commercial production process during the year, marking an important step towards formal preclinical testing and a future FDA marketing submission. The company has progressed the initial nerve conduit program to commercial product scale up stage ahead of its launch later in 2026. ReNerve maintained commercial momentum throughout FY26, with quarterly sales increasing from $66,000 in the September quarter to $97,000 in the December quarter, $135,000 in the March quarter and $211,000 in the June quarter. March 2026 was the first month in which the company recorded sales of more than $100,000. The stronger performance was driven primarily by growth in the Empliq range and the increasing contribution of multiple products to the company’s revenue base. The broader portfolio allows ReNerve to offer hospitals and surgeons a more comprehensive selection of products through the same sales and distribution channels established for the NervAlign Nerve Cuff. During the year, the company continued to progress new hospital approvals. Three new hospital approvals were secured for the Empliq range during the March quarter, with further applications submitted across six targeted hospital systems. These approvals support adoption across the broader ReNerve portfolio and provide an established pathway for the introduction of future products, subject to regulatory clearance. The United States remained ReNerve’s principal commercial market during FY26. The company continued to build its network of distribution partners, engage surgeons and pursue approvals within individual hospital systems. A significant milestone was the approval of the NervAlign Nerve Cuff for purchasing through the United States Department of Defense and Department of Veterans Affairs healthcare networks. This provides a simplified purchasing pathway across a network of more than 1,000 military hospitals, clinics, medical centers and outpatient facilities. ReNerve ended the first half with 21 distribution partners operating across the United States. The combination of distributor coverage, hospital approvals, surgeon engagement and supporting clinical evidence provides a platform from which the company can expand sales of both its existing products and future additions to the NervAlign portfolio. ReNerve launched the Empliq human tissue product range during FY26, achieving its first sale of the Empliq Deep Dermal product during the September quarter and its first sales of the Empliq amniotic tissue products in October 2025. The range includes a deep dermal product for reconstructive and cosmetic surgical applications and three amniotic tissue product ranges used to support wound healing. The company introduced the products to surgeons at the American Society for Surgery of the Hand conference in October 2025 and subsequently progressed hospital approvals and commercial adoption through its existing sales channels. In June 2026, ReNerve appointed J4 Biologics as a second approved manufacturing partner for the Empliq range. J4 is a United States-based human tissue processor specialising in amnion and dermal products. Its appointment followed a qualification and evaluation process covering ReNerve’s quality, compliance and production requirements. ReNerve Limited Directors' report 30 June 2026 4 The second manufacturing relationship was established in response to growing demand and increasing hospital adoption. It is intended to expand available manufacturing capacity, improve product availability, shorten lead times and reduce supply concentration risk. The arrangement also gives the company greater flexibility to scale Empliq inventory production in line with demand. ReNerve made significant progress in extending its commercial footprint across the Asia-Pacific region during FY26. The NervAlign Nerve Cuff received market registration in Malaysia and broader listing approval in Hong Kong, including access to public and private hospitals and hospitals operating within the Greater Bay Area. These approvals complemented ReNerve’s existing market access in jurisdictions including the United States, New Zealand and Thailand. Following the Hong Kong approval, ReNerve entered into an exclusive distribution agreement with Swedish Trading Company covering Hong Kong, Macau and the Greater Bay Area. Swedish Trading Company has established relationships across hospitals and surgical networks in the region and is responsible for importation, warehousing, marketing, sales and distribution. The first stocking orders were shipped into the region during the year. ReNerve also appointed UG Medical as its commercialisation partner in Malaysia. UG Medical will support importation, regulatory management, warehousing, marketing and distribution of the NervAlign product range through its established Malaysian hospital network. ReNerve will provide clinical and technical support, product training and regulatory liaison as commercial activities progress. Subsequent to the end of the financial year, the company secured marketing approval for the NervAlign Nerve Cuff in each of India, Indonesia and the Philippines. These are all very significant markets for the growth prospects of ReNerve, with large populations, high road trauma burdens and therefore outstanding market opportunities for the company. The FDA-cleared NervAlign Nerve Cuff is a bioabsorbable protective wrap designed to provide an environment that supports nerve healing following surgical repair. The product is naturally absorbed within approximately six months of surgery, making it unique in terms of its handling characteristics, its absorption within an ideal time period relative to nerve repair and clean manufacturing process resulting in a clean, safe nerve protective nerve cuff. During FY26, ReNerve continued its post-market clinical evaluation of the Nerve Cuff, building on statistically significant interim data presented in March 2025. The interim analysis showed that patients treated with the NervAlign Nerve Cuff experienced a reduction in average pain scores from 7.1 before surgery to 0.4 after surgery, compared with a reduction from 7.1 to 3.3 among patients receiving the standard of care without the device. Based on the successful outcomes from this study, ReNerve has initiated a more comprehensive study to illustrate the utility and benefits of the NervAlign Nerve Cuff in the repair of injured nerves. The clinical evidence continued to support surgeon engagement, hospital purchasing applications and regulatory submissions in new markets. ReNerve continued to develop its NervAlign Nerve Conduit range during the year. The conduits use the company’s proprietary eCOO™ biomaterial technology and are designed to facilitate nerve growth across short gaps between severed nerve ends. During the early part of FY26, ReNerve finalised the production hardware and manufacturing process for the first products in the conduit range. Development and regulatory work continued during the remainder of the year, with preparations underway for the planned introduction of the product in selected markets, including Malaysia. The Nerve Conduit is expected to broaden the NervAlign portfolio and allow the company to address nerve injuries that require support across a physical gap, complementing the protective function of the existing Nerve Cuff. The Nerve Conduit has a broader appeal due to the use of nerve conduits globally being a larger segment of the nerve repair market compared to nerve cuffs. The NervAlign Nerve Guide Matrix is being developed as a ready-to-use solution for the repair or replacement of more severely injured nerves. The product is intended to provide surgeons with an alternative to donor nerve grafts, which can be constrained by limited availability and require patients to undergo an additional nerve-harvesting procedure. During FY26, ReNerve and its development partner progressed the volume production of prototype Nerve Guide Matrix products. The program subsequently entered Stage 3 of the company’s four-stage scaled commercial production process. Stage 3 represents the manufacturing verification phase and is expected to generate product for formal preclinical testing, associated packaging development and manufacture of the final product configuration. Completion of Stage 3 is targeted for ReNerve Limited Directors' report 30 June 2026 5 the end of calendar 2026. Stage 4 will involve the final production and testing of Nerve Guide Matrix batches ahead of a formal marketing submission. ReNerve continued to engage with the FDA during the development process, with testing activities being designed in consideration of the feedback received. The program has previously generated positive preclinical results in a nerve regeneration model, supporting the potential of the Nerve Guide Matrix as an alternative for the repair and replacement of injured or damaged nerves. ReNerve completed a significant Board renewal process during FY26 to strengthen governance, commercial oversight and strategic capability as the company progresses its transition from a development-stage company towards commercialisation. Ms Maja McGuire was appointed as an Independent Non-Executive Director and Interim Chair on 4 December 2025 and subsequently appointed Non-Executive Chair on 19 December 2025. Dr Paul Savage was appointed as an Independent Non- Executive Director on 4 December 2025. Together, the appointments add substantial expertise in governance, medical technology, manufacturing innovation, commercial strategy and ASX-listed company leadership. The Board renewal process coincided with the retirement of Mr Stephen Cooper and Dr Michael Panaccio from the Board. Dr David Rhodes stepped down as a Director effective 30 April 2026 after nine years of service on the Board. Dr Rhodes remained with ReNerve as Chief Scientific Officer, retaining responsibility for supporting the company’s research and development activities and the delivery of its next generation of products. During the year, ReNerve completed a $3.2 million capital raising. Approximately $2.6 million was received during the December quarter, with the remaining approximately $0.6 million received following shareholder approval and settlement in January 2026. In February 2026, the company received a Research and Development Tax Incentive refund of $517,133 relating to eligible activities undertaken during the 2025 financial year. The refund recognised ReNerve’s continued investment in its proprietary biomaterial and medical device programs. ReNerve recorded customer cash receipts of $382,739 during FY26. Net cash used in operating activities was approximately $5.80 million, reflecting continued investment in product manufacturing, commercial expansion, staffing and corporate activities. During the year, the company increased its investment in the Nerve Guide Matrix program, which entered Stage 3 during the June quarter. The company held cash and cash equivalents of approximately $1.49 million at 30 June 2026. Key risks and uncertainties The company is subject to risks specific to its business activities, as well as general risks. The major risks and uncertainties are summarised below. Successful Commercialisation of Assets The nature of medical device research and development is inherently uncertain at times. There are substantial risks including that clinical studies may fail to achieve acceptable endpoints for efficacy or safety, or the products may not secure acceptance from surgeons and clinicians. Failure in any of these areas would have a material impact on the company’s prospects. ReNerve seeks to mitigate risk through a diversified product pipeline, a maturing portfolio of products some of which are on market, continuous engagement with surgeons, careful design of its clinical studies, and collaboration with reputable and experienced partners. Research and Development Risk ReNerve’s ongoing and future projects require research and development. It is possible that the development of its product portfolio may be more costly or take more time than expected, or may not achieve the expected clinical endpoints. Delays or increased costs could materially impact the company’s ability to bring products to market or achieve commercial milestones. Regulatory and Product Approval Risks As a medical device company, ReNerve’s products are subject to stringent regulatory approval processes in each jurisdiction. The loss, delay or failure to secure required approvals (such as FDA clearance or comparable authorities in other markets) may prevent the commercialisation of its products or expose the company to additional costs and delays. The withdrawal or suspension of existing approvals could significantly affect operations and financial performance. ReNerve monitors regulatory developments and maintains relationships with regulatory consultants and agencies to manage this risk. ReNerve Limited Directors' report 30 June 2026 6 Product Acceptance and Commercial Risks ReNerve relies on acceptance of its products by surgeons. If products are not accepted by surgeons or fail to generate repeat usage, commercial uptake may be limited. The company mitigates this risk through active engagement with opinion leaders, development of clinical data, and education initiatives. Intellectual Property and Competitive Risk ReNerve’s strategy is to rely on a combination of proprietary know-how, trade secrets, and, to a lesser extent, patents. There is a material risk that competitors could seek to reverse-engineer or copy the company’s products, or develop superior alternatives. If ReNerve’s trade secrets are not adequately protected, or if key intellectual property is lost or circumvented, it could harm the company’s market position. The company proactively manages confidentiality but acknowledges some risks are outside its control. Manufacturing, Supply Chain, and Dependency on Key Partners ReNerve’s lead products are currently manufactured by a single supplier (EMCM) under an exclusivity agreement that depends on meeting certain obligations. Loss of exclusivity or termination of the supply agreement - whether through default, insolvency, or operational disruption—would require rapid transition to alternative suppliers, which may not be feasible without significant disruption and cost, although ReNerve has identified an alternative manufacturer. Key raw materials (porcine tissue) are sourced from the Netherlands and could be subject to disruption by disease outbreaks or export restrictions although